The Expression and Clinical Significance of ALDOA in Breast Cancer.

IF 2.8 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2025-08-04 eCollection Date: 2025-01-01 DOI:10.2147/OTT.S518473

Yuning Dai, Yong Yang, Xiaohua Li, Guojian Shi, Ting Ni, Qilu Zhu, Qin He, Aoni Hu, Hao Jiang, Jianxia Liu, Ting Lu, Jie Sun, Enqiao Yu, Liang Sun

{"title":"The Expression and Clinical Significance of ALDOA in Breast Cancer.","authors":"Yuning Dai, Yong Yang, Xiaohua Li, Guojian Shi, Ting Ni, Qilu Zhu, Qin He, Aoni Hu, Hao Jiang, Jianxia Liu, Ting Lu, Jie Sun, Enqiao Yu, Liang Sun","doi":"10.2147/OTT.S518473","DOIUrl":null,"url":null,"abstract":"Background: Several malignant tumors have been shown to overexpress aldolase A (ALDOA), a crucial enzyme in the glycolytic cycle. Though, it is still unknown how ALDOA contributes to breast cancer (BC).Methods: Using GEPIA, TIMER, UALCAN, BC-GenExMiner v5.1 database, and immunohistochemistry on 96 BC patients, the expression of ALDOA was investigated. The correlation between ALDOA expression and the prognosis was evaluated by employing the Kaplan-Meier (KM) plotter in breast cancer patients.Results: The expression of ALDOA mRNA was higher in BC compared to the normal tissues. Certain subtypes of BC showed higher ALDOA expression, including micropapillary, luminal B, non-basal-like, non-triple negative breast cancer (TNBC), and luminal androgen receptor (LAR). Overexpression of ALDOA was related to the presence of lymph node metastasis (LNM), older age, high Ki67 expression, estrogen receptor (ER) and progesterone receptor (PR) positivity, and advanced Scarff-Bloom-Richardson (SBR) and Nottingham Prognostic Index (NPI) grades, while decreased ALDOA mRNA levels were observed in TNBC and basal-like BC. KM plotter showed that higher ALDOA mRNA levels predicted worse overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) overall. However, in BC patients with LNM, higher ALDOA levels correlated to better DMFS.Conclusion: ALDOA was a crucial prognostic factor required for BC advancement, indicating a possible target for BC treatment.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"18 ","pages":"845-862"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S518473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Several malignant tumors have been shown to overexpress aldolase A (ALDOA), a crucial enzyme in the glycolytic cycle. Though, it is still unknown how ALDOA contributes to breast cancer (BC).

Methods: Using GEPIA, TIMER, UALCAN, BC-GenExMiner v5.1 database, and immunohistochemistry on 96 BC patients, the expression of ALDOA was investigated. The correlation between ALDOA expression and the prognosis was evaluated by employing the Kaplan-Meier (KM) plotter in breast cancer patients.

Results: The expression of ALDOA mRNA was higher in BC compared to the normal tissues. Certain subtypes of BC showed higher ALDOA expression, including micropapillary, luminal B, non-basal-like, non-triple negative breast cancer (TNBC), and luminal androgen receptor (LAR). Overexpression of ALDOA was related to the presence of lymph node metastasis (LNM), older age, high Ki67 expression, estrogen receptor (ER) and progesterone receptor (PR) positivity, and advanced Scarff-Bloom-Richardson (SBR) and Nottingham Prognostic Index (NPI) grades, while decreased ALDOA mRNA levels were observed in TNBC and basal-like BC. KM plotter showed that higher ALDOA mRNA levels predicted worse overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) overall. However, in BC patients with LNM, higher ALDOA levels correlated to better DMFS.

Conclusion: ALDOA was a crucial prognostic factor required for BC advancement, indicating a possible target for BC treatment.

查看原文本刊更多论文

ALDOA在乳腺癌中的表达及临床意义。

背景：一些恶性肿瘤已被证明过表达醛缩酶A (ALDOA)，这是糖酵解循环中的一种关键酶。然而，ALDOA如何导致乳腺癌（BC）仍不清楚。方法：应用GEPIA、TIMER、UALCAN、BC- genexminer v5.1数据库，结合免疫组化对96例BC患者进行ALDOA表达的检测。应用Kaplan-Meier （KM）绘图仪评价乳腺癌患者ALDOA表达与预后的相关性。结果：BC组织中ALDOA mRNA的表达明显高于正常组织。某些BC亚型显示较高的ALDOA表达，包括微乳头状、腔内B型、非基底样、非三阴性乳腺癌（TNBC）和腔内雄激素受体（LAR）。ALDOA过表达与淋巴结转移（LNM）、年龄、Ki67高表达、雌激素受体（ER）和孕激素受体（PR）阳性、高级scarf - bloom_richardson （SBR）和Nottingham预后指数（NPI）分级有关，而在TNBC和基底样BC中观察到ALDOA mRNA水平降低。KM绘图仪显示，ALDOA mRNA水平越高，总体上总生存期（OS）、无复发生存期（RFS）和远端无转移生存期（DMFS）越差。然而，在BC合并LNM的患者中，较高的ALDOA水平与较好的DMFS相关。结论：ALDOA是BC进展所需的关键预后因素，提示BC治疗的可能靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.